Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD) (DECO)

Iconic Therapeutics

Status and phase: Terminated; Phase 2

Conditions: Choroidal Neovascularization; Wet Macular Degeneration

Treatments: Biological: ICON-1; Biological: aflibercept

Study type: Interventional

Funder types: Industry

Identifiers

NCT03452527

IT-004

Details and patient eligibility

About

The purpose of this study is to evaluate the safety and effects of repeated intravitreal injections of ICON-1 0.6 mg administered as maintenance therapy or in combination with aflibercept in patients with wet macular degeneration.

Enrollment: 15 patients

Sex: All

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Males or females of any race, ≥50 years of age
• Active primary CNV secondary to AMD in the study eye

Exclusion criteria

• Any prior treatment of CNV or advanced AMD in the study eye, except for dietary supplements or vitamins
• Any intraocular or ocular surface surgery (including cataract surgery and laser procedures) in the study eye within 3 months
• Vitrectomy in the study eye

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

15 participants in 2 patient groups

ICON-1 maintenance therapy

Experimental group

Description:

ICON-1 maintenance therapy after initial aflibercept treatment

Treatment:

Biological: aflibercept

Biological: ICON-1

ICON-1 combination therapy

Experimental group

Description:

ICON-1 combination therapy with aflibercept treatment

Treatment:

Biological: aflibercept

Biological: ICON-1